Please provide your email address to receive an email when new articles are posted on . The approval follows positive results from the TATE trial. A new 10 mg dose will be available to accommodate ...

Dr. Michael Wechsler, Professor of Medicine and Director of The Asthma Institute at National Jewish Health, and International Coordinating Investigator of the MANDARA trial said: “This approval is ...

The FDA approved on Wednesday AstraZeneca Plc’s (NASDAQ:AZN) Fasenra (benralizumab) for eosinophilic granulomatosis with polyangiitis (EGPA), a rare, immune-mediated vasculitis (inflammation of the ...

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss Syndrome, is a rare autoimmune disorder characterized by necrotizing vasculitis of small-to medium-sized blood ...

AstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab), for use in children. The regulatory body has now approved Fasenra as an add-on maintenance ...

Teaming with the Professional Pickleball Association (PPA) in a multiyear deal, AstraZeneca’s seven-year-old Fasenra asthma medication has launched its first-ever sports partnership. The brand began ...

Princess U. Ogbogu, Division Chief of Pediatric Allergy, Immunology, and Rheumatology at University Hospitals Rainbow Babies and Children’s Hospital and Case Western Reserve University, Cleveland, OH, ...

With its latest campaign for the eosinophilic asthma treatment Fasenra, its manufacturer, AstraZeneca, is expanding beyond its usual target demographic, women ages 35 to 68, to try to reach a younger ...

During weeks 48 through 52, a 100% reduction in the OCS dose was observed in 41% of benralizumab-treated patients vs 26% of mepolizumab-treated patients. The Food and Drug Administration (FDA) has ...

FASENRA also demonstrated a greater improvement in fatigue symptom relief in a single monthly dose compared to placebo Princess U. Ogbogu, Division Chief of Pediatric Allergy, Immunology, and ...

Positive full results from the NATRON Phase III trial showed AstraZeneca’s FASENRA(benralizumab) demonstrated a statistically significant delay in the time to first worsening or flare in ...